Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.65 GBX
-2.67%
Market Closed
Updated:
Apr 28, 2024
Fusion Antibodies PLC
Income from Continuing Operations
|
Fusion Antibodies PLC
Income from Continuing Operations Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Income from Continuing Operations
-£2.8m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Income from Continuing Operations
-£154.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Income from Continuing Operations
-£776k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Income from Continuing Operations
£724k
|
CAGR 3-Years
22%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Income from Continuing Operations
£15m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Income from Continuing Operations
£16.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fusion Antibodies PLC's Income from Continuing Operations?
Income from Continuing Operations
-2.8m
GBP
-2.8m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Income from Continuing Operations amounts to -2.8m GBP.
What is Fusion Antibodies PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-17%
-17%
Over the last year, the Income from Continuing Operations growth was -64%. The average annual Income from Continuing Operations growth rates for Fusion Antibodies PLC have been -60% over the past three years , -17% over the past five years .
You don't have any saved screeners yet
